ProQR Therapeutics NV
(NAS:PRQR)
$
1.665
-0.035 (-2.06%)
Market Cap: 135.97 Mil
Enterprise Value: 46.30 Mil
PE Ratio: 0
PB Ratio: 3.60
GF Score: 47/100 - ProQR Therapeutics NV R&D Day TranscriptMar 29, 2023
- ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview TranscriptDec 22, 2022
- ProQR Therapeutics NV Management Call TranscriptAug 11, 2022
- ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call TranscriptApr 13, 2022
- ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call TranscriptFeb 11, 2022
- ProQR Therapeutics NV Analyst Event TranscriptNov 18, 2021
- ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- ProQR Therapeutics NV Axiomer RNA Call TranscriptSep 09, 2021
- ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald TranscriptMar 25, 2021
- ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP TranscriptMar 24, 2021
- ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- ProQR Therapeutics NV Expert Perspectives Call TranscriptFeb 22, 2021
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- LCA10 and Sepofarsen - Call TranscriptJul 20, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call TranscriptJun 22, 2020
ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) Transcript
Mar 09, 2021 / 12:00PM GMT
Release Date Price:
$4.72
(+5.59%)
Andrew S. Fein
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good morning, everyone. My name is Andrew Fein. I'm one of the biotechnology analysts with H.C. Wainwright. It's my pleasure to host a fireside chat this morning with ProQR Therapeutics. Joining from the company is Smital Shah, Chief Business Officer; as well as the Chief Financial Officer of the company. So thank you, Smital, very much for joining us.
Smital Shah
ProQR Therapeutics N.V. - Chief Business & Financial Officer
Thank you, Andrew, and thank you, H.C. Wainwright for hosting us.
Questions & Answers
Andrew S. Fein
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Our pleasure. So maybe the best place to begin in light of upcoming catalysts is with 421a. You guys recently held a KOL event that I thought was very, very useful. So maybe you can begin by overviewing the program and just kind of laying out what folks ought
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)